10.02.2021
"C-reactive protein triggers cell death in ischemic cells":
In the Research Topic "Diagnostic and Therapeutic Applications of Pentraxin and Pentraxin-Associated Proteins" of the journal Frontiers in Immunology, a review on the pathomechanism of CRP in organ-damaging inflammation was published.
12.09.2020
In this article, the current scientific knowledge of the pathological function of CRP is concisely summarized and the therapeutic concept of CRP apheresis is explained in detail on the basis of the clinical CAMI-1 study (after myocardial infarction) and CASTRO-1 study (after stroke).
30.08.2020
In the scientific journal Frontiers in Immunology an article was published in which the effect of human CRP on blood pressure and heart rate of rabbits was investigated.
07.06.2020
In the American Journal of Case Reports the application of PentraSorb® CRP in a COVID-19 patient published.
28.02.2020
Another case report on CRP apheresis was published in the journal Blood purification über die CRP-Aphererse veröffentlicht.
01.06.2019
The first data acquired within the CAMI1 study were again described and published within the magazine NephroNews.
29.03.2019
First data on the treatment of myocardial infarction patients were published in the journal Therapeutic Apheresis and Dialysis.
06.11.2018
The article describes for the first time the treatment of a patient after an acute myocardial infarction (STEMI) with the PentraSorb® CRP. The patient was treated twice with immunapheresis and tolerated the treatment without side effects. The CRP concentration could be reduced by approx. 45%.
